Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Lumbar Discectomy With Annular Closure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03986580
Recruitment Status : Not yet recruiting
First Posted : June 14, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Intrinsic Therapeutics

Brief Summary:
The purpose of this prospective, single-arm, multicenter study is to confirm the efficacy of the Barricaid® when used as an adjunct to a primary lumbar limited discectomy, to limited discectomy alone, with regard to preventing reherniation and the recurrence of pain or dysfunction in a US population.

Condition or disease Intervention/treatment Phase
Lumbar Disc Herniation Device: BARRICAID device Not Applicable

Detailed Description:
This single-arm case series will enroll 75 patients at select US (approximately 8-10) sites. Patients that are scheduled for a single-level L4-S1 discectomy and who meet the pre-operative eligibility criteria will be considered for study participation. Patients that meet all intraoperative criteria will be enrolled into the study and treated with lumbar discectomy and additional annular closure device implantation. All enrolled subjects will be followed for at least 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Evaluation Of Lumbar Discectomy With Additional Implantation Of An Annular Closure Device In Patients With Large Postsurgical Annular Defects For Prevention Of Lumbar Disc Reherniation
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
BARRICAID device
Single arm study; all patients treated with BARRICAID device
Device: BARRICAID device
BARRICAID device, following limited discectomy procedure at a single LS level between L4 and S1




Primary Outcome Measures :
  1. Blood loss [ Time Frame: Intra-operative ]
    Amount of blood loss measured in ml

  2. Procedure time [ Time Frame: Intra-operative ]
    Length of surgery, measured in minutes

  3. Hospital stay [ Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery) ]
    Length of the hospital stay measured in days between hospital admission and hospital discharge

  4. Discharge status [ Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery) ]
    Evaluation of improvement in motor and sensory neurologic status

  5. Leg pain severity (0-100 VAS score) [ Time Frame: Baseline, 4 Weeks, 3 Months, 1 year ]
    Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome

  6. Back pain severity (0-100 VAS score) [ Time Frame: Baseline, 4 Weeks, 3 Months, 1 year ]
    Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome

  7. ODI [ Time Frame: Baseline, 4 Weeks, 3 Months, 1 year ]
    Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability

  8. EQ-5D [ Time Frame: Baseline, 4 Weeks, 3 Months, 1 year ]
    Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension

  9. Satisfaction with surgery procedure [ Time Frame: 1 year ]
    Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others

  10. Neurological assessment [ Time Frame: Baseline, 4 Weeks, 3 Months, 1 year ]
    Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as "normal", "increased", "absent" and "decreased") and muscle strength measured 0-5 with "0" representing no evidence of motor strength and "5" representing full resistance

  11. Adverse events [ Time Frame: Baseline, Intra-operative, 4 Weeks, 3 Months, 1 year ]
    Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure

  12. Hospital readmission occurrence [ Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year ]
    Change from baseline in incidence of re-admissions to hospital, post treatment

  13. Symptomatic reherniation incidence [ Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year ]
    Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review

  14. Reoperation incidence [ Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year ]
    Change from baseline in incidence of post-operative reoperation at the index level

  15. Return to work assessment [ Time Frame: 4 Weeks, 3 Months, 1 year ]
    Change from baseline in work status (ability to return to work, with or without reported restrictions)

  16. Opioid consumption [ Time Frame: Baseline, Intra-operative, Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year ]
    Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 to 75 years old and skeletally mature (male or female)
  2. Subjects with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. [Note: Intraoperatively, only patients with an anular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.]
  3. At least six (6) weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections.;
  4. Minimum posterior disc height of 5mm at the index level.
  5. Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees)
  6. Oswestry Questionnaire score of at least 40/100 at baseline.
  7. VAS leg pain (one or both legs) of at least 40/100 at baseline.
  8. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.

Exclusion Criteria:

  1. Spondylolisthesis Grade II or higher (25% slip or greater).
  2. Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed).
  3. Subject has back or non-radicular leg pain of unknown etiology.
  4. Prior surgery at the index lumbar vertebral level
  5. Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.
  6. Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
  7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip
  8. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).
  9. Any metabolic bone disease.
  10. Subject has an active infection either systemic or local.
  11. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.
  12. Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.)
  13. Subject has significant peripheral neuropathy, defined as a subject with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.
  14. Subject has insulin-dependent diabetes mellitus.
  15. Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight).
  16. Subject has been diagnosed with active hepatitis, AIDS, or HIV.
  17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.
  18. Subject has a known allergy to titanium, polyethylene or polyester materials.
  19. Any subject that cannot have a baseline MRI taken.
  20. Subject is pregnant or interested in becoming pregnant in the next 2 years.
  21. Subject has active tuberculosis or has had tuberculosis in the past three (3) years.
  22. Subject has a history of active malignancy: A subject with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.
  23. Subject is immunologically suppressed, received steroids >1 month over the past year.
  24. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.
  25. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.
  26. Subject has a life expectancy of less than three (3) years.
  27. Subject is currently involved in active spinal litigation.
  28. Subject is currently involved in another investigational study.
  29. Subject is incarcerated.
  30. Any contraindication for MRI (e.g. claustrophobia, contrast allergy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03986580


Contacts
Layout table for location contacts
Contact: Kelsey Miller-Torchia, BA 7815580777 ext 132 kmiller@in-thera.com
Contact: Ivan Grzan, BS 7819320222 ext 171 ivan@in-thera.com

Locations
Layout table for location information
United States, Kentucky
Orthopaedic Institute of Western Kentucky Not yet recruiting
Paducah, Kentucky, United States, 42001
Contact: Rebekah Vinson    270-442-9461 ext 2142    RVinson@orthopaedicinstitute.com   
Principal Investigator: Clint P. Hill, MD         
Sub-Investigator: Brandon K. Strenge, MD         
Sponsors and Collaborators
Intrinsic Therapeutics
Investigators
Layout table for investigator information
Study Chair: David H Kim, MD New england Baptist Hospital

Layout table for additonal information
Responsible Party: Intrinsic Therapeutics
ClinicalTrials.gov Identifier: NCT03986580     History of Changes
Other Study ID Numbers: CP-010
First Posted: June 14, 2019    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hernia
Pathological Conditions, Anatomical